github link
Accession IconSRP084270

Inhibition of ERG Activity in Patient Derived Prostate Cancer Xenografts using the Small Molecule Inhibitor YK-4-279

Organism Icon Homo sapiens
Sample Icon 16 Downloadable Samples
Technology Badge IconIllumina HiSeq 2500

Submitter Supplied Information

Description
ERG activity was blocked using YK-4-279 in three subcutaneously implanted ERG+ (LuCaP 23.1, 86.2, and 35) and one ERG- (LuCaP 96) PDX. Tumor volume (TV), body weight (BW), serum prostate specific antigen (PSA), and overall survival (OS) were compared to vehicle treated controls. Changes in gene expression were assessed by RNASeq and tissue microarrays were constructed to assess necrosis, proliferation, apoptosis, microvessel density, and ERG expression. Overall design: RNA sequencing of tumors from from 16 animals (2 control, 2 treated from each of four patient derived xenograft lines) using Illumina HiSeq 2500.
PubMed ID
Total Samples
16
Submitter’s Institution
No associated institution

Samples

Show of 16 Total Samples
Filter
Add/Remove
Accession Code
Title
Sex
Treatment
Subject
Processing Information
Additional Metadata
35_11_Ctrl
male
control
lucap 35: control, sample: 11
NA
96_34_Ctrl
male
control
lucap 96: control, sample: 34
NA
23.1_22_YK-4-279
male
yk-4-279
lucap 23.1: treated with yk-4-279, sample: 22
NA
86.2_29_YK-4-279
male
yk-4-279
lucap 86.2: treated with yk-4-279, sample: 29
NA
23.1_02_Ctrl
male
control
lucap 23.1: control, sample: 02
NA
23.1_14_Ctrl
male
control
lucap 23.1: control, sample: 14
NA
23.1_16_YK-4-279
male
yk-4-279
lucap 23.1: treated with yk-4-279, sample: 16
NA
35_30_Ctrl
male
control
lucap 35: control, sample: 30
NA
35_04_YK-4-279
male
yk-4-279
lucap 35: treated with yk-4-279, sample: 04
NA
86.2_28_Ctrl
male
control
lucap 86.2: control, sample: 28
NA
Loading...